Australia's most trusted
source of pharma news
Tuesday, 09 June 2026
Posted 9 June 2026 PM
Safety concerns have been raised about a cancer drug being launched in Australia after trial results revealed 27 deaths - three times higher than the standard of care.
Switzerland-based ADC Therapeutics is developing Zynlonta, which is sponsored in Australia by Swedish Orphan Biovitrum (SOBI). The CD19-targeting antibody-drug conjugate has already been to PBAC once and after a rejection it is set to return again in July.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.